Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | PGD | P52209 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12540224 | 1.00 | LMNA (0.41) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL13422928 | 0.92 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL805599 | 0.92 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL30828899 | 0.92 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL2749084 | 0.92 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL24066052 | 0.85 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL21001793 | 0.85 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL29183553 | 0.85 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL6530767 | 0.85 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B | |
| SCHEMBL28544198 | 0.85 | TSHR (0.44) | LMNATSHRALDH1A1HSD17B10PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067344-A1 | COMPOUNDS AND MEDICAL DEVICES ACTIVATED WITH SOLVOPHOBIC LINKERS | SOFRADIM PRODUCTION (FR) | 2016-03-10 | — | — | US | disclosed |
| US-9216226-B2 | Compounds and medical devices activated with solvophobic linkers | SOFRADIM PRODUCTION (FR) | 2015-12-22 | — | — | US | disclosed |
| US-20150147395-A1 | COMPOUNDS AND MEDICAL DEVICES ACTIVATED WITH SOLVOPHOBIC LINKERS | SOFRADIM PRODUCTION (FR) | 2015-05-28 | — | — | US | disclosed |
| US-8969473-B2 | Compounds and medical devices activated with solvophobic linkers | SOFRADIM PRODUCTION (FR) | 2015-03-03 | — | — | US | disclosed |
| US-20150050417-A1 | MEDICAL DEVICE WITH INFLAMMATORY RESPONSE-REDUCING COATING | SOFRADIM PRODUCTION (FR) | 2015-02-19 | — | — | US | disclosed |
| US-8956603-B2 | Amphiphilic compounds and self-assembling compositions made therefrom | SOFRADIM PRODUCTION (FR) | 2015-02-17 | — | — | US | disclosed |
| US-8829071-B2 | Medical device with degradation-retarding coating | SOFRADIM PRODUCTION (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20120071974-A1 | MEDICAL DEVICE WITH DEGRADATION-RETARDING COATING | SOFRADIM PRODUCTION (FR) | 2012-03-22 | — | — | US | disclosed |
| US-20120052042-A1 | AMPHIPHILIC COMPOUNDS AND SELF-ASSEMBLING COMPOSITIONS MADE THEREFROM | SOFRADIM PRODUCTION (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120035321-A1 | COMPOUNDS AND MEDICAL DEVICES ACTIVATED WITH SOLVOPHOBIC LINKERS | SOFRADIM PRODUCTION (FR) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067344-A1 | COMPOUNDS AND MEDICAL DEVICES ACTIVATED WITH SOLVOPHOBIC LINKERS | MLEC, ILK, MSN | LMNA 1689/4885TSHR 4003/4885ALDH1A1 2581/4885 |
| US-20150147395-A1 | COMPOUNDS AND MEDICAL DEVICES ACTIVATED WITH SOLVOPHOBIC LINKERS | MLEC, ILK, MSN | LMNA 1689/4885TSHR 4003/4885ALDH1A1 2581/4885 |
| US-20120035321-A1 | COMPOUNDS AND MEDICAL DEVICES ACTIVATED WITH SOLVOPHOBIC LINKERS | MLEC, ILK, MSN | LMNA 1689/4885TSHR 4003/4885ALDH1A1 2581/4885 |
| US-20120052042-A1 | AMPHIPHILIC COMPOUNDS AND SELF-ASSEMBLING COMPOSITIONS MADE THEREFROM | PICALM, ANXA6, SGMS1 | LMNA 419/4885TSHR 4740/4885ALDH1A1 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.